- Patent-protected next-generation small molecule integrin pharmacology: Orally available, selective, non-agonistic and steerable (IP fully owned).
- First oral drug candidate shown to be effective in animals in vivo and entering therapeutic translation for a severe immune-mediated disease in which the target is over-expressed.
- Portfolio of back-up compounds available to support therapeutic translation in further indications with clinical evidence for high responsiveness to integrin inhibition.
- Technology may become applicable to other therapeutically relevant members of the integrin family.
Crystals of one of AlloCyte's advanced lead compounds